Navigation Links
Resverlogix's Success in Inflammation Program Results in 2 Patents Filed
Date:5/19/2009

    Novel small molecules illustrate potential cost effective approach for
    rheumatoid arthritis

    TSX Exchange Symbol: RVX

CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases. Two new patent applications have been filed for novel compounds and their use in regulating inflammatory markers. Inflammatory markers are proteins generated by the body during periods of inflammation. These patents were filed based on the successful results demonstrated in numerous preclinical studies across several disease areas. The particular results achieved in the collagen induced arthritis (CIA) model in rats demonstrated that Resverlogix's proprietary molecules markedly reduced inflammation while improving mobility of arthritic animals.

"Resverlogix's R&D program has made significant strides this past year," said Donald J. McCaffrey, President & CEO of Resverlogix. "The Company has identified several molecules that have the potential for disease modifying effects in inflammatory disorders such as rheumatoid arthritis. Resverlogix's R&D team is continuing to examine the various disease indications in inflammation which would have the greatest potential impact for both patients and payer groups," continued McCaffrey.

A significant unmet medical need exists for safe, effective and economical therapies for specific inflammation markets. For example, a small molecular drug for rheumatoid arthritis is estimated to range in price from US $180 - US $6000 per person per annum. A biologic, or large molecule drug, can cost in the order of US $13,000 - US $30,000 per patient per annum. In 2007, the global market for rheumatoid arthritis alone was estimated to be in excess of US $11 billion a year and is expected to grow to US $27 billion by the year 2015. These important markets require novel therapies to reduce pain and symptoms in a cost efficient manner. Resverlogix's novel small molecules have the illustrated early potential to fill this important gap.

Kenneth Lebioda, Senior Vice President of Business & Corporate Development of Resverlogix stated, "The inflammation market is enormous with many significant unmet needs. Current leading therapeutics such as biologics are effective, but also very expensive. Resverlogix's platform technology has created novel small molecules which illustrate potent anti-inflammatory effects in arthritis models as compared with leading biologic agents." Lebioda highlighted, "The early efficacy data from these compounds is exciting for the reason that small molecules would offer significant cost savings to health systems over current biologic agents."

Inflammation is a normal response of the body to protect tissues from infection, injury or disease. Though it promotes healing, if uncontrolled, the inflammatory response may become harmful. Acute or chronic inflammation is known to play a key role in diverse disease states, such as atherosclerosis and rheumatoid arthritis. Worldwide it is estimated that more than 80 million people suffer from inflammatory diseases.

Resverlogix will be presenting at the BIO Business Forum held at the Convention Center in Atlanta, Georgia on Wednesday, May 20, 2009 at 9:20 am EDT in Room 313.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
2. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
3. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
8. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
9. Addiction Treatment Finds Success Treating Brain Deficiencies through the Belly
10. Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
11. Sundia MediTech and Xcovery Announce Big Success in Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... Nutrafol®, a first-to-market smart-supplement for healthy ... stress related hair loss. With patent-pending formulas for both female hair loss and ... the medical and salon channels nationwide. , Dermatologists, Plastic Surgeons and hair ...
(Date:5/3/2016)... ... 03, 2016 , ... Flagship Biosciences, the leader in ... Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, ... Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in 1999 ...
(Date:5/3/2016)... , ... May 03, 2016 , ... According to world ... for definitive prostate cancer treatment, patients traditionally had two main treatment options: surgery or ... would be made. , New technology has enabled doctors to administer higher doses ...
(Date:5/2/2016)... PHILADELPHIA, PA (PRWEB) , ... May 02, 2016 ... ... is proud to report on the pre-launch success of their revolutionary, veterinarian-designed product ... allowing cats to stalk, trap, and play with their food the way nature ...
Breaking Biology Technology:
(Date:3/15/2016)... 15, 2016 --> ... Transparency Market Research "Digital Door Lock Systems Market - Global ... 2023," the global digital door lock systems market in terms ... and is forecast to grow at a CAGR of 31.8% ... and medium enterprises (MSMEs) across the world and high industrial ...
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
Breaking Biology News(10 mins):